Our Pipeline

HU6 - Potential Best-in-Class Oral Therapy for MASH

• Differentiated Approach: HU6 is a potential best-in-class MASH therapy uniquely positioned to address the underlying causes of this disease.
• Promising Efficacy Profile: In prior trials, HU6 resulted in robust liver-centric effects, with reductions in fat and inflammation (the primary drivers of MASH), along with systemic reductions in fat (particularly visceral fat) while preserving muscle, which is critical for sustained metabolic health.  
• Favorable Safety Profile: With over 500 patients treated to date, HU6 has demonstrated a positive safety and tolerability profile.
• Prominent Presentations: HU6 clinical results have been published in The Lancet Gastroenterology & Hepatology for MASLD, presented in a late-breaker oral presentation at AASLD for MASH, and published in JAMA Cardiology for HFpEF.
• Mechanism: HU6 leverages an energy expenditure mechanism to deliver differentiated cardiometabolic health benefits to MASH patients. HU6 increases energy expenditure through mitochondrial uncoupling, a natural metabolic process responsible for 20-40% of average daily energy expenditure. By increasing mitochondrial uncoupling, patients burn additional calories, primarily from fat, even while at rest. HU6 is metabolized in the liver to provide liver-targeted reductions in fat and inflammation, the primary drivers of MASH.
• MASH Development: We are advancing HU6 in the ongoing AMPLIFY Phase 2 trial ahead of late-stage clinical development for HU6 in MASH. 

RV-8451 - A Highly-Differentiated Oral GLP-1 for Obesity

• Differentiated Approach: RV-8415 is the industry’s first muscle-preserving, oral GLP-1 non-peptide agonist. This highly-differentiated oral GLP-1 is designed to deliver high-quality, fat-specific, durable weight loss with convenient oral dosing. 
• Promising Preclinical Data: Demonstrated body weight reduction and fat loss while preserving lean mass and increasing energy expenditure. RV-8451 also demonstrated the potential to improve additional metabolic parameters. Importantly, RV-8451 treatment was well tolerated. 
• Mechanism: RV-8451 decreases energy intake as a GLP-1 and increases energy expenditure by preserving muscle. 
• Obesity Development: IND-enabling studies are underway to support a planned IND submission for RV-8451 in obesity.